The state of Georgia currently has 19 active clinical trials seeking participants for Migraine research studies. These trials are conducted in various cities, including Atlanta, Augusta, Decatur and Savannah.
Efficacy and Safety of Erenumab in Pediatric Participants With Episodic Migraine
Recruiting
This study will evaluate the efficacy and safety of erenumab in migraine prevention in children (6 to <12 years) and adolescents (12 to <18 years) with episodic migraine. The study hypothesis is that in pediatric participants with episodic migraine, the combined erenumab dose group has a greater reduction from baseline to week 9 through week 12 (month 3) in monthly migraine days (MMDs) when compared with placebo in the double-blind treatment phase (DBTP).
Gender:
All
Ages:
Between 6 years and 17 years
Trial Updated:
06/19/2024
Locations: Rare Disease Research Center Pediatrics, Atlanta, Georgia +1 locations
Conditions: Migraine
Study of Oral Ubrogepant to Assess Adverse Events and Change in Disease Activity in Adult Participants With Menstrual Migraine
Recruiting
A migraine is a moderate to severe headache typically on one side of the head. A migraine attack is a headache that may be accompanied by throbbing, nausea, vomiting, sensitivity to light and sound, or other symptoms. Menstrual migraine (MM) is defined as migraine attacks that occur within the perimenstrual period (PMP) in at least 2 out of 3 menstrual cycles. The PMP is from 2 days before the onset of menstrual bleeding to 2 days after. This study will assess how safe and effective ubrogepant i... Read More
Gender:
Female
Ages:
18 years and above
Trial Updated:
06/18/2024
Locations: Clinical Research Atlanta - Headlands LLC /ID# 260181, Stockbridge, Georgia
Conditions: Migraine
A 12-Month Study of Lasmiditan (LY573144) Treatment in Children Aged 6 to 17 With Migraine
Recruiting
The reason for this 12-month, open-label study is to see if the study drug lasmiditan is safe and effective for the intermittent acute treatment of migraine in children aged 6 to 17. The study will last about 12 months and may include up to 7 visits.
Gender:
All
Ages:
Between 6 years and 17 years
Trial Updated:
06/17/2024
Locations: Meridian Clinical Research, LLC, Savannah, Georgia +1 locations
Conditions: Migraine
A Study of Galcanezumab (LY2951742) in Participants 12 to 17 Years of Age With Chronic Migraine
Recruiting
The main purpose of this study is to evaluate the efficacy and safety of galcanezumab for the preventive treatment of chronic migraine in participants 12 to 17 years of age. The primary objective is to demonstrate the superiority of galcanezumab versus placebo in the reduction of monthly migraine headache days across the 3-month double-blind treatment period.
Gender:
All
Ages:
Between 12 years and 17 years
Trial Updated:
06/17/2024
Locations: Rare Disease Research, LLC, Atlanta, Georgia
Conditions: Chronic Migraine
Randomized Study in Children and Adolescents With Migraine: Acute Treatment
Recruiting
The purpose of this study is to test the safety and efficacy of BHV-3000 versus placebo in the acute treatment of moderate or severe migraine in children and adolescents.
Gender:
All
Ages:
Between 6 years and 17 years
Trial Updated:
06/17/2024
Locations: Children's Healthcare of Atlanta Center for Advanced Pediatrics, Atlanta, Georgia +3 locations
Conditions: Pediatric Migraine
Efficacy and Safety Study of Rimegepant for the Preventative Treatment of Migraine in Pediatric Subjects
Recruiting
The purpose of this study is to compare the efficacy and safety of rimegepant to placebo as a preventative treatment for migraine in children and adolescents ≥ 6 to <18 years with episodic migraine.
Gender:
All
Ages:
Between 6 years and 17 years
Trial Updated:
06/17/2024
Locations: Augusta University, Augusta, Georgia +4 locations
Conditions: Migraine
A Study of Galcanezumab (LY2951742) in Participants 6 to 17 Years of Age With Episodic Migraine
Recruiting
The main purpose of this study is to evaulate the efficacy and safety of galcanezumab in participants 6 to 17 years of age for the preventive treatment of episodic migraine. The primary objective is to demonstrate the superiority of galcanezumab versus placebo in the reduction of monthly migraine headache days across the 3-month double-blind treatment period.
Gender:
All
Ages:
Between 6 years and 17 years
Trial Updated:
06/17/2024
Locations: Rare Disease Research, LLC, Atlanta, Georgia +1 locations
Conditions: Episodic Migraine
A Study of Lasmiditan (LY573144) Treatment in Children Aged 6 to 17 With Migraine
Recruiting
The reason for this study is to see if lasmiditan is safe and effective in children aged 6 to 17 with migraine. The study will last up to 20 weeks and may include up to 4 visits.
Gender:
All
Ages:
Between 6 years and 17 years
Trial Updated:
06/17/2024
Locations: Meridian Clinical Research, LLC, Savannah, Georgia +1 locations
Conditions: Migraine
Efficacy and Safety of Erenumab in Pediatric Subjects With Chronic Migraine
Recruiting
This study will evaluate the efficacy and safety of erenumab in migraine prevention in children (6 to <12 years) and adolescents (12 to <18 years) with chronic migraine. The study hypothesis is that in pediatric participants with chronic migraine, the combined erenumab dose group has a greater reduction from baseline to week 9 through week 12 (month 3) in monthly migraine days (MMDs) when compared with placebo in the double-blind treatment phase (DBTP).
Gender:
All
Ages:
Between 6 years and 17 years
Trial Updated:
06/12/2024
Locations: Rare Disease Research Center Pediatrics, Atlanta, Georgia +1 locations
Conditions: Migraine
Efficacy and Tolerability of Rimegepant for the Acute Treatment of Migraine in Adults Unsuitable for Triptan Use
Recruiting
This study is being conducted to evaluate the efficacy and tolerability of rimegepant in a population of adults that are unsuitable for triptan medications due to a previous intolerance, lack of efficacy, or contraindication (including a history of clinically-relevant cardiovascular disease).
Gender:
All
Ages:
18 years and above
Trial Updated:
06/10/2024
Locations: WR-Mount Vernon Clinical Research, LLC, Sandy Springs, Georgia
Conditions: Migraine
Study to Assess Adverse Events and Disease Activity of Oral Ubrogepant Tablets for the Acute Treatment of Migraine in Children and Adolescents (Ages 6-17)
Recruiting
Migraine is a common neurological disorder typically characterized by attacks of throbbing, moderate to severe headache, often associated with nausea, vomiting, and sensitivity to light and sound. Migraine is extremely common and disabling in children. The purpose of this study is to evaluate how safe and effective ubrogepant is in the acute treatment of migraine in children and adolescents. Ubrogepant is a drug approved for the acute treatment of migraine in adults. Children and adolescents (a... Read More
Gender:
All
Ages:
Between 6 years and 17 years
Trial Updated:
06/05/2024
Locations: Treken Primary Care /ID# 240586, Atlanta, Georgia +6 locations
Conditions: Migraine
Long-term Safety Study of Rimegepant in Pediatric Subjects for the Acute Treatment of Migraine
Recruiting
The purpose of this study is to test the long-term safety of rimegepant in the acute treatment of moderate or severe migraine in children and adolescents (≥ 6 to < 18 years of age).
Gender:
All
Ages:
Between 6 years and 17 years
Trial Updated:
05/31/2024
Locations: Children's Healthcare of Atlanta - Center for Advanced Pediatrics, Atlanta, Georgia +3 locations
Conditions: Acute Treatment of Migraine